ARRY Array BioPharma Inc.

8.27
-0.07  -1%
Previous Close 8.34
Open 8.41
Price To book 51.17
Market Cap 1.41B
Shares 170,800,000
Volume 2,038,329
Short Ratio 4.49
Av. Daily Volume 4,107,320

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828549
  2. 8-K - Current report 17828535
  3. 8-K - Current report 17828354
  4. 8-K - Current report 17820626
  5. 8-K - Current report 17787944

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet its primary endpoint - August 2016
Selumetinib - SELECT-1
Differentiated thyroid cancer
Phase 3 data released September 26, 2016 met primary endpoint. Data from Part 2 portion of trial due released May 9, 2017. NDA filing due June or July 2017.
Binimetinib - COLUMBUS
BRAF mutant melanoma cancer
Phase 2 data presented at the European Society of Cardiology on August 30, 2016. Phase 3 trial to be initiated in summer 2017.
ARRY 797
LMNA A/C-related dilated cardiomyopathy (DCM)
Phase 2 interim data due 2016 but no plans to advance program
ARRY-520 (Filanesib)
Refractory Multiple Myeloma Cancer
Phase 3 trial discontinued April 2016
Binimetinib - MILO
Recurrent low-grade serous ovarian cancer (LGSOC)
PDUFA date originally set for June 30, 2017. Announed withdrawl of NDA filing - March 20, 2017.
Binimetinib (NEMO)
NRAS melanoma - cancer
Phase 3 initiated June 2016. SPA announced September 2016. Randomization part of trial now enrolling. Expects to present early data from the safety lead-in later in 2017..
Encorafenib and cetuximab - BEACON CRC
BRAF-Mutant Colorectal Cancer

Latest News

  1. Blog Coverage: Mirna Announced Reverse Merger Agreement
  2. Edited Transcript of ARRY earnings conference call or presentation 10-May-17 1:00pm GMT
  3. Today's Research Reports on Stocks to Watch: Array Biopharma and Verastem
  4. Array Biopharma Sees Positive Study Results From COLUMBUS Phase 2, But Commercialization May Prove Daunting
  5. Here's Why the Market's Overlooking Array Biopharma Inc.'s Earnings Miss Today
  6. Investor Network: Array BioPharma Inc. to Host Earnings Call
  7. Array BioPharma reports 3Q loss
  8. Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017
  9. Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma
  10. Array BioPharma Announces Strategic Collaboration with Merck
  11. Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma
  12. Array Biopharma To Report Financial Results For The Third Quarter Of Fiscal 2017 On May 10, 2017
  13. Shalini Sharp Joins Array BioPharma Board of Directors
  14. If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss
  15. Today's Research Reports on Biotech Stocks to Watch: Array Biopharma and ImmunoGen
  16. Do Options Traders Know Something About Array BioPharma (ARRY) Stock We Don't?
  17. Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down
  18. Will Array Biopharma's Melanoma Drugs Keep the Stock Soaring?
  19. How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
  20. Array Biopharma Withdraws Cancer Drug Application